2020 04 v.36 685-691
COVID-19疫苗的研究进展
基金项目(Foundation):
湖北省知识创新专项(项目号:2019CFC865),题目:柯萨奇病毒A6病毒样颗粒的免疫原性及保护性研究;;
湖北省技术创新专项(重大项目,项目号:141),题目:手足口病双价灭活疫苗的研制;;
国家“重大新药创制”科技重大专项(项目号:2015ZX09102021),题目:人肠道病毒71型及柯萨奇病毒A16型双价灭活疫苗的研制;;
三峡大学人才专项经费(项目号:20171227)~~
邮箱(Email):
DOI:
10.13242/j.cnki.bingduxuebao.003717
中文作者单位:
三峡大学医学院;三峡大学附属仁和医院;武汉生物制品研究所病毒性疫苗研究一室;苏州华益美生物科技有限公司;
摘要(Abstract):
新型冠状病毒肺炎(Coronavirus disease 2019,COVID-19)是由新型冠状病毒(Severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)引起的一种新的传染病。阻止COVID-19流行最有效的方法就是研制安全有效的疫苗,目前国内外多家机构开展了COVID-19疫苗的研究,包括核酸疫苗、病毒载体疫苗、灭活疫苗、重组蛋白疫苗、减毒流感病毒载体疫苗等不同类型,并取得了快速进展。本文对COVID-19疫苗的类型、研究进展、存在的问题等进行综述。
关键词(KeyWords):
新型冠状病毒肺炎;;2019新型冠状病毒;;疫苗
| 5,590 | 6 | 26 |
| 下载次数 | 被引频次 | 阅读次数 |
参考文献
[1]David S H, Esam I A, Tariq A M, Francine N,Richard K,Osman D,Giuseppe I,Timothy D M,Ziad A M, Christian D, Alimuddin Z, Eskild P. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan,China[J]. Int J Infect Dis,2020,91:264-266.
[2]Kumar S, Poonam, Rathi B. Coronavirus disease COVID-19:A new threat to public health[J]. Curr Top Med Chem,2020,20(8):599-600
[3]关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知[2020-03-04]. http://www. nhc. gov. cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[4]Lu R,Zhao X,Li J,Niu P,Yang B,Wu H,Wang W,Song H,Huang B,Zhu N,Bi Y,Ma X,Zhan F,Wang L,Hu T,Zhou H,Hu Z,Zhou W,Zhao L,Chen J,Meng Y,Wang J,Lin Y,Yuan J,Xie Z,Ma J,Liu W J,Wang D,Xu W,Holmes E C,Gao G F,Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J].Lancet,2020,395(10224):565-574.
[5]Paul S Masters. The molecular biology of coronaviruses[J]. Adv Virus Res,2006,66:193-292.
[6]Kirchdoerfer R N,Cottrell C A,Wang N,Pallesen J,Yassine H M,Turner H L,Corbett K S,Graham B S,McLellan J S,Ward A B. Pre-fusion structure of a human coronavirus spike protein[J]. Nature,2016,531:118-121.
[7]Chen Y,Guo Y,Pan Y,Zhao Z J.Structure analysis of the receptor binding of 2019-nCoV[J/OL]. Biochem Biophys Res Commun, 2020, DOI:10.1016/j.bbrc.2020.02.071.
[8]Wu A,Peng Y,Huang B,Ding X,Wang X,Niu P,Meng J,Zhu Z,Zhang Z,Wang J,Sheng J,Quan L,Xia Z, Tan W, Cheng G, Jiang T. Genome composition and divergence of the novel coronavirus(2019-nCoV)originating in China[J]. Cell Host Microbe,2020,27(3):325-328.
[9]Zhang W,Du R H,Li B,Zheng X S,Yang X L,Hu B,Wang Y Y,Xiao G F,Yan B,Shi Z L,Zhou P.Molecular and serological investigation of 2019-nCoV infected patients:implication of multiple shedding routes[J]. Emerg Microbes Infect,2020,9(1):386–389.
[10]Hoffmann M,Kleine W H,Schroeder S,Krüger N,Herrler T,Erichsen S,Schiergens T S,Herrler G,Wu N H,Nitsche A,Müller M A,Drosten C,P?hlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell,2020,181(2):271-280.
[11]Wrapp D,Wang N,Corbett K S,Goldsmith J A,Hsieh C L,Abiona O,Graham B S,McLellan J S.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J].Science,2020,367(6483):1260-1263.
[12]Yan R,Zhang Y,Li Y,Xia L,Guo Y,Zhou Q.Structural basis for the recognition of the SARS-CoV-2by full-length human ACE2[J]. Science, 2020,367(6485):1444-1448.
[13]Qiu T,Mao T,Wang Y,Zhou M,Qiu J,Wang J,Xu J,Cao Z. Identification of potential cross-protective epitope between a new type of coronavirus(2019-nCoV)and severe acute respiratory syndrome virus[J].J Genet Genomics,2020,47(2):115-117.
[14]Lan J,Ge J,Yu J,Shan S,Zhou H,Fan S,Zhang Q,Shi X,Wang Q,Zhang L,Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor[J]. Nature, 2020,581(7807):215-220.
[15]Zheng M,Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2compared to SARS-CoV[J/OL]. Cell Mol Immunol,2020,17(5):536-538.
[16]Yuan M,Wu N C,Zhu X,Lee C D,So R T Y,Lv H,Mok C K P,Wilson I A. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2and SARS-CoV[J/OL].Science. 2020,pii:eabb7269.
[17]孔琪. SARS灵长类动物模型[J].中国实验动物学报,2005,13(3):131-131.
[18]Wang Q,Zhang L,Kuwahara K,Li L,Liu Z,Li T,Zhu H,Liu J,Xu Y,Xie J,Morioka H,Sakaguchi N,Qin C, Liu G. Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Non-human Primates[J].ACS Infect Dis,2016,2(5):361-376.
[19]孔琪. SARS啮齿类动物模型[J].中国实验动物学报,2005,13(3):143-143.
[20]杨秀红,陈云新,朱华,黄澜,马春梅,刘亚莉,秦川.hACE2转基因小鼠SARS-CoV感染后的病理变化及免疫学反应[J].基础医学与临床,2008,28(6):595-599.
[21]Yang X H,Deng W,Tong Z,Liu Y X,Zhang L F,Zhu H,Gao H,Huang L,Liu YL,Ma C M,Xu Y F,Ding M X,Deng H K,Qin C. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection[J]. Comp Med,2007,57(5):450-459.
[22]Pong W. A dozen vaccine programs under way as WHO declares coronavirus public health emergency.Biocentury. 2020. https://www.biocentury.com/article/304328/industry-and-academic-centers-are-rushing-tocreate-new-vaccines-and-therapeutics-targetingcoronavirus. Accessed 28 Feb 2020.
[23]Safety and immunogenicity study of 2019-nCoV vaccine(mRNA-1273)for prophylaxis SARS CoV-2 infection.Clinical trials. gov https://clinicaltrials. gov/ct2/show/NCT04283461? type=Intr&cond=COVID-19&phase=04&draw=3&rank=26
[24]Inovio pharmaceuticals. inovio collaborating with beijing advaccine to advance INO-4800 vaccine against new coronavirus in China[DB/OL]. 2020. http://ir. inovio.com/news-and-media/news/press-release-details/2020/Inovio-Collaborating-With-Beijing-Advaccine-ToAdvance-INO-4800-Vaccine-Against-New-CoronavirusIn-China/default.aspx. Accessed 28 Feb 2020.
[25]A Phase I Clinical Trial in 18-60 Adults. ClinicalTrials.gov.https://clinicaltrials.gov/ct2/show/NCT04313127? type=Intr&cond=COVID-19&phase=04&draw=2&rank=10
[26]Chen W H,Strych U,Hotez P J,Bottazzi M E. The SARS-CoV-2 vaccine pipeline:an overview[J/OL].Curr Trop Med Rep,2020 Mar 3:1-4. DOI:10.1007/s40475-020-00201-6.
[27]国务院联防联控机制2020年4月14日新闻发布会-介绍新冠肺炎药物研发、疫苗研制等科研攻关进展情况[Z].中华人民共和国国家卫生和计划生育委员会,2020-4-14. http://www. nhc. gov. cn/xwzb/webcontroller.do?titleSeq=11296&gecstype=1
[28]国务院联防联控机制2020年3月17日新闻发布会-介绍药物疫苗和检测试剂研发攻关最新情况[Z].中华人民共和国国家卫生和计划生育委员会,2020-03-17.http://www. nhc. gov. cn/xwzb/webcontroller. do?titleSeq=11266&gecstype=1
[29]Vennema H,Groot R J,Harbour D A,Dalderup M,Gruffydd J T,Horzinek M C,Spaan W J. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization[J]. J Virol,1990,64(3):1407-1409.
[30]Luo F,Liao F L,Wang H,Tang H B,Yang Z Q,Hou W. Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine[J]. Virol Sin,2018,33(2):201-204.
[31]Liu L,Wei Q,Lin Q,Fang J,Wang H,Kwok H,Tang H,Nishiura K,Peng I,Tan Z,Wu T,Cheung K W,Chan K H,Alvarez X,Qin C,Lackner A,Perlman S,Yuen K Y,Chen Z. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection[J/OL]. JCI Insight,2019,4(4):e123158. DOI:10.1172/jci.insight.123158
[32]Tetro J A. Is COVID-19 receiving ADE from other coronaviruses?[J].Microbes Infect,2020,22(2):72-73.
[33]Tang X,Wu C,Li X,Song Y,Yao X,Wu X,Duan Y,Zhang H,Wang Y,Qian Z,Cui J,Lu J. On the origin and continuing evolution of SARS-CoV-2[J/OL].Natl Sci Rev,2020,7(6):1012-1023.
[34]Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines:Lessons learned from SARS and MERS epidemic[J].Asian Pac J Allergy Immunol,2020,38(1):1-9.
[2]Kumar S, Poonam, Rathi B. Coronavirus disease COVID-19:A new threat to public health[J]. Curr Top Med Chem,2020,20(8):599-600
[3]关于印发新型冠状病毒肺炎诊疗方案(试行第七版)的通知[2020-03-04]. http://www. nhc. gov. cn/yzygj/s7653p/202003/46c9294a7dfe4cef80dc7f5912eb1989.shtml.
[4]Lu R,Zhao X,Li J,Niu P,Yang B,Wu H,Wang W,Song H,Huang B,Zhu N,Bi Y,Ma X,Zhan F,Wang L,Hu T,Zhou H,Hu Z,Zhou W,Zhao L,Chen J,Meng Y,Wang J,Lin Y,Yuan J,Xie Z,Ma J,Liu W J,Wang D,Xu W,Holmes E C,Gao G F,Wu G, Chen W, Shi W, Tan W. Genomic characterisation and epidemiology of 2019 novel coronavirus:implications for virus origins and receptor binding[J].Lancet,2020,395(10224):565-574.
[5]Paul S Masters. The molecular biology of coronaviruses[J]. Adv Virus Res,2006,66:193-292.
[6]Kirchdoerfer R N,Cottrell C A,Wang N,Pallesen J,Yassine H M,Turner H L,Corbett K S,Graham B S,McLellan J S,Ward A B. Pre-fusion structure of a human coronavirus spike protein[J]. Nature,2016,531:118-121.
[7]Chen Y,Guo Y,Pan Y,Zhao Z J.Structure analysis of the receptor binding of 2019-nCoV[J/OL]. Biochem Biophys Res Commun, 2020, DOI:10.1016/j.bbrc.2020.02.071.
[8]Wu A,Peng Y,Huang B,Ding X,Wang X,Niu P,Meng J,Zhu Z,Zhang Z,Wang J,Sheng J,Quan L,Xia Z, Tan W, Cheng G, Jiang T. Genome composition and divergence of the novel coronavirus(2019-nCoV)originating in China[J]. Cell Host Microbe,2020,27(3):325-328.
[9]Zhang W,Du R H,Li B,Zheng X S,Yang X L,Hu B,Wang Y Y,Xiao G F,Yan B,Shi Z L,Zhou P.Molecular and serological investigation of 2019-nCoV infected patients:implication of multiple shedding routes[J]. Emerg Microbes Infect,2020,9(1):386–389.
[10]Hoffmann M,Kleine W H,Schroeder S,Krüger N,Herrler T,Erichsen S,Schiergens T S,Herrler G,Wu N H,Nitsche A,Müller M A,Drosten C,P?hlmann S. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor[J]. Cell,2020,181(2):271-280.
[11]Wrapp D,Wang N,Corbett K S,Goldsmith J A,Hsieh C L,Abiona O,Graham B S,McLellan J S.Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation[J].Science,2020,367(6483):1260-1263.
[12]Yan R,Zhang Y,Li Y,Xia L,Guo Y,Zhou Q.Structural basis for the recognition of the SARS-CoV-2by full-length human ACE2[J]. Science, 2020,367(6485):1444-1448.
[13]Qiu T,Mao T,Wang Y,Zhou M,Qiu J,Wang J,Xu J,Cao Z. Identification of potential cross-protective epitope between a new type of coronavirus(2019-nCoV)and severe acute respiratory syndrome virus[J].J Genet Genomics,2020,47(2):115-117.
[14]Lan J,Ge J,Yu J,Shan S,Zhou H,Fan S,Zhang Q,Shi X,Wang Q,Zhang L,Wang X. Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor[J]. Nature, 2020,581(7807):215-220.
[15]Zheng M,Song L. Novel antibody epitopes dominate the antigenicity of spike glycoprotein in SARS-CoV-2compared to SARS-CoV[J/OL]. Cell Mol Immunol,2020,17(5):536-538.
[16]Yuan M,Wu N C,Zhu X,Lee C D,So R T Y,Lv H,Mok C K P,Wilson I A. A highly conserved cryptic epitope in the receptor-binding domains of SARS-CoV-2and SARS-CoV[J/OL].Science. 2020,pii:eabb7269.
[17]孔琪. SARS灵长类动物模型[J].中国实验动物学报,2005,13(3):131-131.
[18]Wang Q,Zhang L,Kuwahara K,Li L,Liu Z,Li T,Zhu H,Liu J,Xu Y,Xie J,Morioka H,Sakaguchi N,Qin C, Liu G. Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Non-human Primates[J].ACS Infect Dis,2016,2(5):361-376.
[19]孔琪. SARS啮齿类动物模型[J].中国实验动物学报,2005,13(3):143-143.
[20]杨秀红,陈云新,朱华,黄澜,马春梅,刘亚莉,秦川.hACE2转基因小鼠SARS-CoV感染后的病理变化及免疫学反应[J].基础医学与临床,2008,28(6):595-599.
[21]Yang X H,Deng W,Tong Z,Liu Y X,Zhang L F,Zhu H,Gao H,Huang L,Liu YL,Ma C M,Xu Y F,Ding M X,Deng H K,Qin C. Mice transgenic for human angiotensin-converting enzyme 2 provide a model for SARS coronavirus infection[J]. Comp Med,2007,57(5):450-459.
[22]Pong W. A dozen vaccine programs under way as WHO declares coronavirus public health emergency.Biocentury. 2020. https://www.biocentury.com/article/304328/industry-and-academic-centers-are-rushing-tocreate-new-vaccines-and-therapeutics-targetingcoronavirus. Accessed 28 Feb 2020.
[23]Safety and immunogenicity study of 2019-nCoV vaccine(mRNA-1273)for prophylaxis SARS CoV-2 infection.Clinical trials. gov https://clinicaltrials. gov/ct2/show/NCT04283461? type=Intr&cond=COVID-19&phase=04&draw=3&rank=26
[24]Inovio pharmaceuticals. inovio collaborating with beijing advaccine to advance INO-4800 vaccine against new coronavirus in China[DB/OL]. 2020. http://ir. inovio.com/news-and-media/news/press-release-details/2020/Inovio-Collaborating-With-Beijing-Advaccine-ToAdvance-INO-4800-Vaccine-Against-New-CoronavirusIn-China/default.aspx. Accessed 28 Feb 2020.
[25]A Phase I Clinical Trial in 18-60 Adults. ClinicalTrials.gov.https://clinicaltrials.gov/ct2/show/NCT04313127? type=Intr&cond=COVID-19&phase=04&draw=2&rank=10
[26]Chen W H,Strych U,Hotez P J,Bottazzi M E. The SARS-CoV-2 vaccine pipeline:an overview[J/OL].Curr Trop Med Rep,2020 Mar 3:1-4. DOI:10.1007/s40475-020-00201-6.
[27]国务院联防联控机制2020年4月14日新闻发布会-介绍新冠肺炎药物研发、疫苗研制等科研攻关进展情况[Z].中华人民共和国国家卫生和计划生育委员会,2020-4-14. http://www. nhc. gov. cn/xwzb/webcontroller.do?titleSeq=11296&gecstype=1
[28]国务院联防联控机制2020年3月17日新闻发布会-介绍药物疫苗和检测试剂研发攻关最新情况[Z].中华人民共和国国家卫生和计划生育委员会,2020-03-17.http://www. nhc. gov. cn/xwzb/webcontroller. do?titleSeq=11266&gecstype=1
[29]Vennema H,Groot R J,Harbour D A,Dalderup M,Gruffydd J T,Horzinek M C,Spaan W J. Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization[J]. J Virol,1990,64(3):1407-1409.
[30]Luo F,Liao F L,Wang H,Tang H B,Yang Z Q,Hou W. Evaluation of antibody-dependent enhancement of SARS-CoV infection in rhesus macaques immunized with an inactivated SARS-CoV vaccine[J]. Virol Sin,2018,33(2):201-204.
[31]Liu L,Wei Q,Lin Q,Fang J,Wang H,Kwok H,Tang H,Nishiura K,Peng I,Tan Z,Wu T,Cheung K W,Chan K H,Alvarez X,Qin C,Lackner A,Perlman S,Yuen K Y,Chen Z. Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection[J/OL]. JCI Insight,2019,4(4):e123158. DOI:10.1172/jci.insight.123158
[32]Tetro J A. Is COVID-19 receiving ADE from other coronaviruses?[J].Microbes Infect,2020,22(2):72-73.
[33]Tang X,Wu C,Li X,Song Y,Yao X,Wu X,Duan Y,Zhang H,Wang Y,Qian Z,Cui J,Lu J. On the origin and continuing evolution of SARS-CoV-2[J/OL].Natl Sci Rev,2020,7(6):1012-1023.
[34]Prompetchara E, Ketloy C, Palaga T. Immune responses in COVID-19 and potential vaccines:Lessons learned from SARS and MERS epidemic[J].Asian Pac J Allergy Immunol,2020,38(1):1-9.
基本信息:
DOI：10.13242/j.cnki.bingduxuebao.003717
中图分类号:R392-33
引用信息:
[1]陈静,李波,申硕等.COVID-19疫苗的研究进展[J].病毒学报,2020,36(04):685-691.DOI:10.13242/j.cnki.bingduxuebao.003717.
基金信息:
湖北省知识创新专项(项目号:2019CFC865),题目:柯萨奇病毒A6病毒样颗粒的免疫原性及保护性研究;; 湖北省技术创新专项(重大项目,项目号:141),题目:手足口病双价灭活疫苗的研制;; 国家“重大新药创制”科技重大专项(项目号:2015ZX09102021),题目:人肠道病毒71型及柯萨奇病毒A16型双价灭活疫苗的研制;; 三峡大学人才专项经费(项目号:20171227)~~
暂无数据